April 10, 2009 - The results of the ZEST randomized controlled trial released at ACC 2009 showed the Cypher Sirolimus-eluting Coronary Stent significantly outperformed the Endeavor and Taxus Liberte in the key clinical outcomes of ischemia-driven target lesion revascularization (TLR) and stent thrombosis through one year.
